Treatment of idiopathic pulmonary fibrosis (IPF). Slows the rate of decline in pulmonary function in patients w/ systemic sclerosis associated interstitial lung disease (SSc-ILD). Treatment of other chronic fibrosing interstitial lung diseases w/ a progressive phenotype (progressive fibrosing ILD).
Reports of GI disorders eg, diarrhoea, nausea & vomiting; arterial thromboembolic events; wt loss. Patients at higher CV risk including known CAD. Consider treatment interruption in case of signs or symptoms of acute myocardial ischemia. May increase BP; systemic BP should be measured periodically & as clinically indicated thereafter. Patients w/ clinically significant pulmonary HTN. Patients w/ known risk of GI perforation. Increased risk of bleeding. Associated w/ elevations of liver enzymes & bilirubin; monitor hepatic transaminase & bilirubin levels before treatment initiation, then mthly during the 1st 3 mth of treatment, periodically thereafter or as clinically indicated. Not recommended in patients w/ moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment. Patients w/ severe renal impairment (CrCl <30 mL/min). Lactation.